Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

7.470 -0.030 (-0.40%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kezar Life Sciences Inc

< Previous 1 2 3 4 Next >
Looking Into Kezar Life Sciences's Recent Short Interest
Via Benzinga
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected in... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Analyst Expectations for Kezar Life Sciences's Future
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. 
Via Benzinga
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. 
Via InvestorPlace
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology. 
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick. 
Via InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await. 
Via InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth. 
Via InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Via Benzinga
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.